The parties acknowledge that Histogenics will be permitted, and may be required pursuant to the rules and regulations promulgated under the Securities Exchange Act of 1934, as amended, to file a Current Report on Form 8-K disclosing the entry into this First Amendment by Histogenics and a brief description of the terms and conditions hereof that are material to Histogenics. To the extent that Histogenics reasonably determines that it is required to make a filing or any other public disclosure (other than as set forth in the preceding sentence) with respect to this First Amendment or the terms or existence hereof to comply with the requirements, rules, laws or regulations of any applicable stock exchange, Nasdaq or any governmental or regulatory authority or body, including without limitation the U.S. Securities and Exchange Commission (the “SEC”) (collectively, the “Disclosure Obligations”), Histogenics shall promptly inform Purpose thereof and shall use reasonable efforts to maintain the confidentiality of Purpose’s confidential information in any such filing or disclosure. Prior to making any such filing of a copy of this First Amendment, the parties shall mutually agree on the provisions of this First Amendment for which the parties shall seek confidential treatment, it being understood that if one party determines to seek confidential treatment for a provision for which the other party does not, then the parties will use reasonable efforts in connection with such filing to seek the confidential treatment of any such provision. The parties shall cooperate, each at its own expense, in such filing, including without limitation such confidential treatment request, and shall execute all documents reasonably required in connection therewith. In furtherance of the foregoing, the parties will agree as promptly as practicable after the First Amendment Effective Date on the confidential treatment request to be filed with the SEC and the redacted form of this First Amendment related thereto. In furtherance thereof, any redaction reasonably requested by either party shall be included in such filing. The parties will reasonably cooperate in responding promptly to any comments received from the SEC with respect to such filing in an effort to achieve confidential treatment of such redacted form; provided, however, that a party shall be relieved of such obligation to seek confidential treatment for a provision requested by the other party if such treatment is not achieved after the **** round of responses to comments from the SEC. Notwithstanding anything to the contrary in the Agreement, Histogenics may make reference to the existence of this First Amendment and the Agreement and describe in general terms the relationship between the parties in connection with any required securities filings without seeking Purpose’s prior consent. This paragraph shall apply with respect to the filing of a copy of this First Amendment or any public disclosure relating to this First Amendment to comply with the Disclosure Obligations.